Willingness-to-Pay Assessment

Willingness-to-pay assessment quantitates patient monetary value perception for pharmaceutical benefits. Stated preference methods elicit hypothetical payment willingness. Revealed preference analysis examines actual purchasing behaviour. Discrete choice experiments estimate preference intensity. Price sensitivity thresholds guide commercial decisions.

Reimbursement strategies account for willingness-to-pay findings. Pricing models incorporate preference data. Regulatory submissions address value communication. Post-approval monitoring tracks actual adoption. Patient education emphasises value propositions.